Veronique Serre-Beinier

Mrs. Veronique Serre-Beinier

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DCDidier J. Colin
Didier J. Colin
DCDavid Cottet-Dumoulin
David Cottet-Dumoulin
FAFaivre Anna
Faivre Anna
SGStéphane Germain
Stéphane Germain
FTFrederic Triponez
Frederic Triponez
VSVeronique Serre-Beinier
Veronique Serre-Beinier
Malignant pleural mesothelioma (MPM) is a thoracic aggressive cancer caused by asbestos exposure, which is difficult to diagnose and treat. Here, we characterized an in vivo orthotopic xenograft model consisting of human mesothelioma cells (designed as H2052/484) derived from a pleural NCI-H2052 tumor injected in partially immunodeficient athymic mice. We assessed tumor formation and tumor-dependent patterns of inflammation. H2052/484 cells conserved their mesothelioma phenotype and most characteristics from the parental NCI-H2052 cells. After intra-thoracic injection of H2052/484 cells, thoracic tumors developed in nearly all mice (86%) within 14 days, faster than from parental NCI-H2052 cells. When the mice were euthanized, the pleural lavage fluid was examined for immune cell profiles. The pleural immune cell population increased with tumor development. Interestingly, the proportion of myeloid-derived suppressor cell and macrophage (especially CD206+ M2 macrophages) populations increased in the pleural fluid of mice with large mesothelioma development, as previously observed in immunocompetent mice. This reliable orthotopic model recapitulates human mesothelioma and may be used for the study of new treatment strategies.

23 February 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
Licun WuLicun Wu
Licun Wu
MKMikihiro Kohno
Mikihiro Kohno
JMJunichi Murakami
Junichi Murakami
AZAmin Zia
Amin Zia
JAJonathan Allen
Jonathan Allen
MPMarc de Perrot
Marc de Perrot
Defining the ontogeny of tumor-associated macrophages (TAM) is important to develop therapeutic targets for mesothelioma. We identified two distinct macrophage populations in mouse peritoneal and pleural cavities, the monocyte-derived, small peritoneal/pleural macrophages (SPM), and the tissue-resident large peritoneal/pleural macrophages (LPM). SPM rapidly increased in tumor microenvironment after tumor challenge and contributed to the vast majority of M2-like TAM. The selective depletion of M2-like TAM by conditional deletion of the Dicer1 gene in myeloid cells (D −/− ) promoted tumor rejection. Sorted SPM M2-like TAM initiated tumorigenesis in vivo and in vitro, confirming their capacity to support tumor development. The transcriptomic and single-cell RNA sequencing analysis demonstrated that both SPM and LPM contributed to the tumor microenvironment by promoting the IL-2-STAT5 signaling pathway, inflammation, and epithelial–mesenchymal transition. However, while SPM preferentially activated the KRAS and TNF-α/NFkB signaling pathways, LPM activated the IFN-γ response. The importance of LPM in the immune response was confirmed by depleting LPM with intrapleural clodronate liposomes, which abrogated the antitumoral memory immunity. SPM gene signature could be identified in pleural effusion and tumor from patients with untreated mesothelioma. Five genes, TREM2, STAB1, LAIR1, GPNMB , and MARCO , could potentially be specific therapeutic targets. Accordingly, Trem2 gene deletion led to reduced SPM M2-like TAM with compensatory increase in LPM and slower tumor growth. Overall, these experiments demonstrate that SPM M2-like TAM play a key role in mesothelioma development, while LPM more specifically contribute to the immune response. Therefore, selective targeting of monocyte-derived TAM may enhance antitumor immunity through compensatory expansion of tissue-resident TAM.

4 March 2014 in British Journal of Cancer
Verified
Journal Article
Open access
COC Otterstrom
C Otterstrom
ASA Soltermann
A Soltermann
IOI Opitz
I Opitz
Emanuela Felley-BoscoEmanuela Felley-Bosco
Emanuela Felley-Bosco
WWW Weder
W Weder
VSVeronique Serre-Beinier
Veronique Serre-Beinier
The pro-inflammatory cytokine migration inhibitory factor (MIF) and its receptor CD74 have been proposed as possible therapeutic targets in several cancers. We studied the expression of MIF and CD74 together with calretinin in specimens of malignant pleural mesothelioma (MPM), correlating their expression levels with clinico-pathologic parameters, in particular overall survival (OS). Migration inhibitory factor, CD74, and calretinin immunoreactivity were investigated in a tissue microarray of 352 patients diagnosed with MPM. Protein expression intensities were semiquantitatively scored in the tumour cells and in the peritumoral stroma. Markers were matched with OS, age, gender, and histological subtype. Clinical data from 135 patients were available. Tumour cell expressions of MIF and CD74 were observed in 95% and 98% of MPM specimens, respectively, with a homogenous distribution between the different histotypes. CD74 (P<0.001) but not MIF overexpression (P=0.231) emerged as an independent prognostic factor for prolonged OS. High expression of tumour cell calretinin correlated with the epithelioid histotype and was also predictive of longer OS (P<0.001). When compared with previously characterised putative epithelial-to-mesenchymal transition markers, CD74 correlated positively with tumoral PTEN and podoplanin expressions, but was inversely related with periostin expression. High expression of CD74 is an independent prognostic factor for prolonged OS in mesothelioma patients.

9 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DGDylan A.J. Gendre
Dylan A.J. Gendre
EAEdis Ameti
Edis Ameti
WKWolfram Karenovics
Wolfram Karenovics
NPNadja Perriraz-Mayer
Nadja Perriraz-Mayer
FTFrédéric Triponez
Frédéric Triponez
VSVeronique Serre-Beinier
Veronique Serre-Beinier
Https://doi.org/10.18632/oncotarget.28134 Dylan A.J. Gendre, Edis Ameti, Wolfram Karenovics, Nadja Perriraz-Mayer, Frédéric Triponez, Véronique Serre-Beinier

12 August 2025 in Nature Metabolism
Verified
Journal Article
Open access
JZJoséphine Zangari
Joséphine Zangari
OSOliver Stehling
Oliver Stehling
SFSven A. Freibert
Sven A. Freibert
KBKaushik Bhattacharya
Kaushik Bhattacharya
FRFlorian Rouaud
Florian Rouaud
JMJean-claude Martinou
Jean-claude Martinou
Selective targeting of cancer cells is a major challenge for cancer therapy. Many cancer cells overexpress the cystine/glutamate antiporter xCT/CD98, an l-cystine transport system that strengthens antioxidant defences, thereby promoting tumour survival and progression. Here, we show that the d-enantiomer of cysteine (d-Cys) is selectively imported into xCT/CD98-overexpressing cancer cell lines and impairs their proliferation, particularly under high oxygen concentrations. Intracellular d-Cys specifically inhibits the mitochondrial cysteine desulfurase NFS1, a key enzyme of cellular iron–sulfur protein biogenesis, by blocking sulfur mobilization due to steric constraints. NFS1 inhibition by d-Cys affects all cellular iron–sulfur cluster-dependent functions, including mitochondrial respiration, nucleotide metabolism and maintenance of genome integrity, leading to decreased oxygen consumption, DNA damage and cell cycle arrest. d-Cys administration diminishes tumour growth of human triple-negative breast cancer cells implanted orthotopically into the mouse mammary gland. Hence, d-Cys could represent a simple therapy to selectively target those forms of cancer characterized by overexpression of xCT/CD98.

1 January 2019 in Lung Cancer
Verified
Journal Article
Closed access
Licun WuLicun Wu
Licun Wu
IDIrene Dell'Anno
Irene Dell'Anno
MLMoshe Lapidot
Moshe Lapidot
YSYoshitaka Sekido
Yoshitaka Sekido
MCMei-Lin Chan
Mei-Lin Chan
MPMarc de Perrot
Marc de Perrot